137 related articles for article (PubMed ID: 15839129)
1. Another popular painkiller gets the government's hook.
Querna E
US News World Rep; 2005 Apr; 138(14):47. PubMed ID: 15839129
[No Abstract] [Full Text] [Related]
2. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
3. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Epstein RA
Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
[No Abstract] [Full Text] [Related]
4. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
5. Proposed NSAID package insert labeling.
Food and Drug Administration U.S. Public Health Service
J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
[TBL] [Abstract][Full Text] [Related]
6. Valdecoxib for the management of chronic and acute pain.
Joshi GP
Expert Rev Neurother; 2005 Jan; 5(1):11-24. PubMed ID: 15853470
[TBL] [Abstract][Full Text] [Related]
7. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Vanchieri C
J Natl Cancer Inst; 2005 Apr; 97(8):552-3. PubMed ID: 15840872
[No Abstract] [Full Text] [Related]
8. FDA announces changes affecting the marketing of non-steroidal anti-inflammatory drugs.
FDA Consum; 2005; 39(3):7. PubMed ID: 16127812
[No Abstract] [Full Text] [Related]
9. Regulating off-label drug use--rethinking the role of the FDA.
Stafford RS
N Engl J Med; 2008 Apr; 358(14):1427-9. PubMed ID: 18385495
[No Abstract] [Full Text] [Related]
10. Is it a cosmetic, a drug, or both? (Or is it soap?).
Center for Safety and Applied Nutrition/Office of Cosmetics and Colors US Food and Drug Administration
Plast Surg Nurs; 2008; 28(4):195-7. PubMed ID: 19092587
[No Abstract] [Full Text] [Related]
11. Labeling changes for arthritis drug.
FDA Consum; 2002; 36(5):6. PubMed ID: 12412538
[No Abstract] [Full Text] [Related]
12. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
Willis KD
Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
[No Abstract] [Full Text] [Related]
13. FDA officials argue over safety of new arthritis drug.
Moynihan R
BMJ; 2003 Mar; 326(7389):565. PubMed ID: 12637379
[No Abstract] [Full Text] [Related]
14. The pain game.
Wadman M
Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
[No Abstract] [Full Text] [Related]
15. Valdecoxib: cutaneous and vascular risks.
Prescrire Int; 2005 Apr; 14(76):63. PubMed ID: 15877326
[No Abstract] [Full Text] [Related]
16. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
Leghorn J; Brophy E; Rother P
Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
[No Abstract] [Full Text] [Related]
17. COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
Meechan J
Br J Oral Maxillofac Surg; 2006 Apr; 44(2):163-5. PubMed ID: 16191457
[No Abstract] [Full Text] [Related]
18. A sick agency in need of a cure? Recall of a popular pain drug has focused attention on government drug regulation.
Spake A
US News World Rep; 2004 Dec; 137(21):32-3, 36. PubMed ID: 15636503
[No Abstract] [Full Text] [Related]
19. COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV; Barnett EM; Randels CL
Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
[No Abstract] [Full Text] [Related]
20. A painkiller is pulled from the market. So what do you do now?
Heart Advis; 2004 Dec; 7(12):2. PubMed ID: 15779132
[No Abstract] [Full Text] [Related]
[Next] [New Search]
